ARTICLE
|
doi:10.20944/preprints202111.0447.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immunotherapy; immune-checkpoint inhibitor; response prediction; men and women; pembrolizumab; nivolumab; atezolizumab; ECOG; CRP; chemo-immunotherapy
Online: 24 November 2021 (09:02:46 CET)